Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 + HLX04 in advanced hepatocellular carcinoma
CTR20191104Phase 2Suspended
- Sponsor
- HyBioPharma
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, HLX04-O in hepatocellular carcinoma (HCC), sponsored by HyBioPharma. Started Oct 2019; status: suspended.
02
Drugs
serplulimabHLX04-O
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20191104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191104.